S
Stephen Morris
Researcher at University of Cambridge
Publications - 499
Citations - 19558
Stephen Morris is an academic researcher from University of Cambridge. The author has contributed to research in topics: Cost effectiveness & Health care. The author has an hindex of 63, co-authored 443 publications receiving 16484 citations. Previous affiliations of Stephen Morris include St. John's University & King's College London.
Papers
More filters
Journal ArticleDOI
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Veeru Kasivisvanathan,Antti Rannikko,Marcelo Borghi,Valeria Panebianco,Lance A. Mynderse,Markku H. Vaarala,Alberto Briganti,Lars Budäus,Giles Hellawell,Richard G. Hindley,Monique J. Roobol,Scott E. Eggener,Maneesh Ghei,Arnauld Villers,Franck Bladou,Geert M. Villeirs,Jaspal Virdi,S. Boxler,Grégoire Robert,Paras B. Singh,Wulphert Venderink,Boris Hadaschik,Alain Ruffion,Jim C. Hu,Daniel Margolis,Sebastien Crouzet,Laurence Klotz,Samir S. Taneja,Peter A. Pinto,Inderbir S. Gill,Clare Allen,Francesco Giganti,Alex Freeman,Stephen Morris,Shonit Punwani,Norman R. Williams,Chris Brew-Graves,Jonathan J Deeks,Yemisi Takwoingi,Mark Emberton,Caroline M. Moore +40 more
TL;DR: The use of risk assessment with MRI before biopsy and MRI‐targeted biopsy was superior to standard transrectal ultrasonography–guided biopsy in men at clinical risk for prostate cancer who had not undergone biopsy previously.
Journal ArticleDOI
cIAP1 and cIAP2 Facilitate Cancer Cell Survival by Functioning as E3 Ligases that Promote RIP1 Ubiquitination
Mathieu J.M. Bertrand,Snezana Milutinovic,Kathleen M. Dickson,Wai Chi Ho,Alain Boudreault,Jon P. Durkin,John W. Gillard,James B. Jaquith,Stephen Morris,Philip A. Barker +9 more
TL;DR: It is demonstrated that AEG40730, a compound modeled on BIR-binding tetrapeptides, binds to cI AP1 and cIAP2, facilitates their autoubiquitination and proteosomal degradation, and causes a dramatic reduction in RIP1 ubiquitination.
Journal ArticleDOI
Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal
Nita Agar,Emma Wedgeworth,Siobhan Crichton,Tracey J. Mitchell,Michael E. Cox,Silvia Ferreira,Alistair Robson,Eduardo Calonje,Catherine M. Stefanato,Elizabeth Mary Wain,Bridget S. Wilkins,Paul Fields,Alan Dean,Katherine Webb,Julia Scarisbrick,Stephen Morris,Sean Whittaker +16 more
TL;DR: This study validated the recently proposed ISCL/EORTC staging system and identified new prognostic factors in mycosis fungoides and Sézary syndrome patients.
Journal ArticleDOI
Inequity and inequality in the use of health care in England: an empirical investigation.
TL;DR: This work investigates inequality and inequity in the use of general practitioner consultations, outpatient visits, day cases and inpatient stays in England with a unique linked data set that combines rich information on the health of individuals and their socio-economic circumstances with information on local supply factors.
Journal ArticleDOI
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince,H. Miles Prince,Youn H. Kim,Steven M. Horwitz,Reinhard Dummer,Julia Scarisbrick,Pietro Quaglino,Pier Luigi Zinzani,Pascal Wolter,Jose A Sanches,Pablo L. Ortiz-Romero,Oleg E. Akilov,Larisa J. Geskin,Larisa J. Geskin,Judith Trotman,Kerry Taylor,Stéphane Dalle,Michael Weichenthal,Jan Walewski,David E. Fisher,Brigitte Dréno,Rudolf Stadler,Tatyana Feldman,Timothy M. Kuzel,Yinghui Wang,Maria Corinna Palanca-Wessels,Erin Zagadailov,William L. Trepicchio,Wenwen Zhang,H. Lin,Yi Liu,Dirk Huebner,Meredith Little,Sean Whittaker,Madeleine Duvic,David Joske,Ian D. Lewis,Constanze Jonak,Franz Trautinger,Oliver Bechter,Dominique Bron,Vladmir Cláudio Cordeiro de Lima,José Antonio Sanches,Richard Klasa,Martine Bagot,Marie Beylot-Barry,Michel D'Incan,Florent Grange,Jan P. Nicolay,Marion Wobser,Chalid Assaf,Carmen Loquai,Michele Spina,Alberto Bosi,Pier Paolo Fattori,Aleksandra Grzanka,Andres Lopez-Hernandez,Jose Juan Rifon Roca,Silvana Novelli Canales,Timothy M Illidge,Rod Johnson,Stephen Morris,Pam McKay,O. Akilov,Steve Horwitz,Barbara Pro,Timothy Kuzel,Adam Lerner,Herbert Eradat,Lubomir Sokol,David C. Fisher,Sarah Hughey +71 more
TL;DR: Significant improvement in objective response lasting at least 4 months was seen with brentuximab vedotin versus physician's choice of methotrexate or bexarotene in previously treated patients with CD30-positive cutaneous T-cell lymphomas.